Therapy

Corvas And Dyax Collaborate On Serine Protease Inhibitors

Published in Cancer Weekly, October 30th, 2001

Corvas International Inc. and Dyax Corp. have agreed to collaborate on the discovery, development, and commercialization of novel cancer therapeutics focused on serine protease inhibitors. Serine proteases, the largest human protease gene family, have been implicated in the growth and progression of solid tumor cancers including breast and prostate cancer.

Dyax will use its phage display technology to identify small proteins, peptides (protein fragments), and antibodies that bind to two serine protease targets isolated and characterized by Corvas. Corvas will apply its expertise in target validation and preclinical biology, including the expression and purification of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry